Warning: Undefined variable $programsFilterHtml in /home/venatorx/public_html/dev.venatorx.com/wp-content/plugins/workbox_manuscripts/plugin.php on line 812
SORT BY PROGRAM


Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States

Publication Date
September 28, 2023

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection

Publication Date
March 21, 2023

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program

Publication Date
January 16, 2023

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/ taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model

Publication Date
January 14, 2023

Bronchopulmonary disposition of IV cefepime/taniborbactam (2–0.5 g) administered over 2 h in healthy adult subjects

Publication Date
December 19, 2022

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection

Publication Date
October 26, 2022

In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination

Publication Date
October 5, 2022

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment

Publication Date
August 3, 2022

In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain

Publication Date
March 15, 2022

Activity of cefepime-taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19

Publication Date
February 7, 2022

In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales

Publication Date
January 18, 2022

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes

Publication Date
November 28, 2021

Clinical exposure–response relationship of cefepime-taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model

Publication Date
November 8, 2021

Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor

Publication Date
October 18, 2021

The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli

Publication Date
September 8, 2021

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes

Publication Date
June 30, 2021

Microbiological characterization of VNRX-5236: a broad spectrum β-lactamase inhibitor for rescue of the orally bioavailable cephalosporin ceftibuten as a carbapenem-sparing agent against strains of Enterobacterales expressing extended spectrum β-lactamases and serine carbapenemases.

Publication Date
May 7, 2021

Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in In Vitro Checkerboard Assays

Publication Date
March 18, 2021

Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model

Publication Date
February 19, 2021

Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales

Publication Date
November 24, 2020

Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections

Publication Date
October 28, 2020

Activity of beta-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria

Publication Date
October 9, 2020

Metallo-Beta-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline

Publication Date
September 21, 2020

In vivo pharmacodynamics of new-generation beta-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-beta-lactamase-producing Gram-negative bacteria

Publication Date
August 30, 2020

In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China

Publication Date
July 15, 2020

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-Beta-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa

Publication Date
December 23, 2019

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-Beta-Lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections

Publication Date
November 25, 2019

Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases

Publication Date
August 27, 2019

Interplay between beta-lactamases and new beta-lactamase inhibitors

Publication Date
March 5, 2019